Amylyx said its GLP-1 receptor antagonist avexitide delivered a Phase 3 success in post-bariatric hypoglycemia (PBH), cutting serious hypoglycemic events by 55% versus placebo in the pivotal trial. The result, disclosed as part of a late-stage readout, positions the company to pursue FDA approval for a first targeted therapy in PBH after gastric bypass. Amylyx has been rebuilding its pipeline after years in ALS development; the PBH readout reframes the company around endocrine drug development. Multiple reports cite trial statistics that were powered for a 35% improvement over placebo, with the achieved effect larger than expected. Analysts and clinicians are likely to focus next on clinical utility—how quickly benefits emerge, durability over time, and tolerability—alongside FDA expectations for endpoints and safety in a niche but potentially high-need population.